Analyst Ratings for Intellia Therapeutics (NTLA)
NTLA Rating Summary
NTLA Price Target Summary
- Highest: $106.00 (Brookline Capital Markets)
- Lowest: $5.00 (JPMorgan)
- Average: $26.55
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$26.55 (+69.4%)
* Over Last 12-Mos
Rating Score: 6.3 / 10
Percentile Rank: 66%
Avg. $ Target:
$26.55 (+69.4%)
* Over Last 12-Mos
Rating Score: 6.3 / 10
Percentile Rank: 66%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/4/2026 | Jones Trading | Debanjana Chatterjee | Upgrade | Buy (Hold) |
29.00 (N/A) |
13.60 (15.67) |
15.22% | Details |
| 3/2/2026 | William Blair | Myles Minter | Upgrade | Outperform (Market Perform) |
N/A (N/A) |
13.78 (15.67) |
13.72% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
